GSK-3 Inhibitor Therapy for Neurodegeneration

📖 Wiki Page

idea1136 wordssynced 2026-04-02

Overview

flowchart TD ideas_payload_gsk3_inhibitor_t["GSK-3 Inhibitor Therapy for Neurodegeneration"] ideas_payload_gsk3_inhibitor_t["Executive"] ideas_payload_gsk3_inhibitor_t -->|"related to"| ideas_payload_gsk3_inhibitor_t style ideas_payload_gsk3_inhibitor_t fill:#81c784,stroke:#333,color:#000 ideas_payload_gsk3_inhibitor_t["Summary"] ideas_payload_gsk3_inhibitor_t -->|"related to"| ideas_payload_gsk3_inhibitor_t style ideas_payload_gsk3_inhibitor_t fill:#81c784,stroke:#333,color:#000 ideas_payload_gsk3_inhibitor_t["Target"] ideas_payload_gsk3_inhibitor_t -->|"related to"| ideas_payload_gsk3_inhibitor_t style ideas_payload_gsk3_inhibitor_t fill:#81c784,stroke:#333,color:#000 ideas_payload_gsk3_inhibitor_t["Glycogen"] ideas_payload_gsk3_inhibitor_t -->|"related to"| ideas_payload_gsk3_inhibitor_t style ideas_payload_gsk3_inhibitor_t fill:#81c784,stroke:#333,color:#000 style ideas_payload_gsk3_inhibitor_t fill:#4fc3f7,stroke:#333,color:#000

Executive Summary

Target: Glycogen synthase kinase-3 (GSK-3α and GSK-3β) Approach: Inhibit GSK-3 activity to reduce tau hyperphosphorylation, amyloid production, and neuroinflammation Therapeutic Area: Alzheimer's Disease, Parkinson's Disease, ALS, FTD, Bipolar Disorder Score: 78/100

Mechanism of Action

GSK-3 Biology

...

Overview

Mermaid diagram (expand to render)

Executive Summary

Mechanism of Action

GSK-3 Biology

Glycogen synthase kinase-3 (GSK-3) is a serine/threonine kinase with two isoforms: GSK-3α and [GSK-3β](/entities/gsk3-beta). It is one of the most actively studied drug targets in neurodegeneration due to its involvement in multiple pathogenic processes[@beurel2015][@llorensmartin2014].

Key GSK-3 substrates:

[Tau protein](/proteins/tau) (hyperphosphorylation)
[Amyloid precursor protein](/entities/app-protein) (APP) processing
β-catenin (Wnt signaling)
CREB (transcription)
Mitochondrial proteins
Synaptic plasticity regulators

Therapeutic Rationale

GSK-3 is hyperactive in Alzheimer's disease and other neurodegenerative conditions:

Alzheimer's Disease:

GSK-3β activity elevated in AD [hippocampus](/brain-regions/hippocampus)
Drives tau hyperphosphorylation and NFT formation
Increases amyloid-β production through APP processing
Impairs synaptic plasticity and memory
Active in neuroinflammation through [NF-κB](/entities/nf-kb) activation

Parkinson's Disease:

GSK-3 promotes [α-synuclein](/proteins/alpha-synuclein) phosphorylation (Ser129)
Contributes to dopaminergic neuron death
Links to mitochondrial dysfunction

ALS:

[TDP-43](/mechanisms/tdp-43-proteinopathy) phosphorylation by GSK-3
Motor neuron vulnerability

Inhibitor Classes

Several GSK-3 inhibitor classes are in development:

ATP-competitive inhibitors: Tideglusib, CHIR99021, SB-216763

Non-ATP-competitive: VP0.7

Natural products: Lithium, curcumin derivatives

Novel agents: AZD1080, PF-04802367

Lithium remains the best-studied GSK-3 inhibitor but has dose-limiting side effects.

Scoring (10-Dimension Rubric)

| Dimension | Score | Rationale |
|-----------|-------|-----------|
| Novelty | 7 | Well-studied target; several inhibitors in trials |
| Mechanistic Rationale | 9 | Strong genetic and biochemical validation |
| Root-Cause Coverage | 8 | Addresses tau pathology, amyloid, neuroinflammation |
| Delivery Feasibility | 6 | Brain penetration challenging for many inhibitors |
| Safety Plausibility | 6 | Off-target effects, narrow therapeutic window |
| Combinability | 8 | Works with anti-amyloid, [autophagy](/entities/autophagy) enhancers |
| Biomarker Availability | 8 | p-tau levels, kinase activity assays |
| De-risking Path | 7 | Some inhibitors have clinical history |
| Multi-disease Potential | 9 | High across AD, PD, ALS, FTD, BD |
| Patient Impact | 8 | Large disease-modifying potential |

Total: 78/100

Clinical Evidence

Completed Trials

Tideglusib (NP031112):

Phase 2 trial in AD: Primary endpoints not met
Some cognitive benefit observed in apolipoprotein E4 carriers
Generally well-tolerated

Lithium:

Mixed results in AD and PD trials
Low-dose lithium may have neuroprotective effects
Safety concerns at higher doses

Ongoing Trials

Novel GSK-3 inhibitors in preclinical development
Combination approaches with other mechanisms

Development Pathway

Challenges

Therapeutic window: Achieving brain penetration without peripheral toxicity

Isoform selectivity: Targeting β isoform while sparing α

Chronic dosing: Long-term treatment required

Biomarker validation: Need robust p-tau lowering markers

Combination Potential

GSK-3 inhibitors synergize with:

Anti-amyloid antibodies (reduces amyloid-driven GSK-3 activation)
Autophagy inducers (complementary protein clearance)
Tau immunotherapy (different mechanism)
Metabolic modulators (NAD+, GLP-1)

Actionable Next Steps

Lab Experiments

Isoform-selective inhibitor screening: Screen novel GSK-3β-selective inhibitors for brain penetration, prioritizing compounds with >50-fold selectivity over GSK-3α. Use in vitro kinase assays with tau phosphorylation (Ser396) as readout.

Patient-derived neuron testing: Test lead compounds in iPSC-derived [neurons](/entities/neurons) from AD and PD patients. Measure p-tau (Thr231, Ser396), total tau, and amyloid secretion.

Combination synergy studies: Test GSK-3 inhibitors in combination with anti-amyloid antibodies ([lecanemab](/entities/lecanemab), donanemab), autophagy inducers ([TFEB](/entities/tfeb) activators), or NAD+ boosters to identify synergistic combinations.

Clinical Protocol Design

Patient enrichment strategy: Select patients with elevated baseline [p-tau217](/biomarkers/p-tau-217) or p-tau181 in CSF or plasma. Target early-stage AD (MCI due to AD or mild AD dementia).

Dose-finding design: Use staggered low-dose escalation to find optimal brain exposure. Primary endpoint: CSF p-tau reduction at 6 months. Secondary: amyloid PET, cognitive measures.

Biomarker monitoring: Establish p-tau and total tau in CSF as pharmacodynamic markers. Consider tau PET as secondary endpoint.

Company Partnership Opportunities

AstraZeneca/GSK partnership: AZD1080 was discontinued - position novel approach as next-generation with improved brain penetration and selectivity.

Tideglusib (Noscira): Their compound failed - learn from their dosing and formulation experience.

Academic networks: Partner with Alzheimer's Clinical Trial Consortium (ACTC) for trial design and execution.

Implementation Roadmap

Phase 1: Lead Optimization (Months 1-18)

Screen novel GSK-3β-selective inhibitors with CLogP < 3, PSA < 80
Optimize for brain penetration and kinase selectivity
Begin SAR studies for tau phosphorylation inhibition
Budget: $2-4M

Phase 2: IND-Enabling Studies (Months 15-30)

GLP toxicology in rat and cynomolgus monkey (6-month)
CMC development for oral and/or subcutaneous formulation
Biomarker assay development (p-tau in CSF, plasma)
IND package preparation
Budget: $5-8M

Phase 3: Clinical Development (Months 30-60)

Phase 1 safety in healthy volunteers (completed)
Phase 2 dose-finding in early AD patients
Phase 2b registration-enabling trial
Budget: $20-35M

Phase 4: Pivotal Trials (Months 60-96)

Phase 3 registration trials in early AD
NDA/MAA submission
Budget: $60-100M

Total Program Cost: $87-147M over 96 months (8 years)

Key Academic Centers

| Institution | Key Investigators | Relevance |
|------------|------------------|-----------|
| UCL Queen Square | Dr. John Hardy | GSK-3 biology in AD |
| Mayo Clinic Jacksonville | Dr. Leonard Petrucelli | Tau biology, therapeutic targeting |
| UC San Diego | Dr. Paula Desplats | Neurodegeneration, GSK-3 |
| Banner Sun Health | Dr. Thomas Beach | Human brain tissue, biomarker validation |

Industry Partners

| Company | Relevance |
|---------|----------|
| Noscira (Tideglusib) | Failed Phase 2 - learn from experience |
| Lilly | Amyloid antibody combinations |
| Biogen | Tau programs, CNS delivery |

Milestones and Go/No-Go Decision Points

Lead Selection (Month 15)

Go: >100-fold GSK-3β selectivity, brain:plasma >0.3, >50% p-tau reduction in vitro
No-Go: Insufficient selectivity or brain penetration

IND-Enabling Toxicology (Month 30)

Go: NOAEL established in two species, no tumorigenic signals
No-Go: Unexpected toxicity requiring reformulation

Phase 2b Efficacy (Month 60)

Go: >20% slowing of clinical decline (CDR-SB), significant p-tau reduction
No-Go: Insufficient efficacy - pivot to combination therapy or prevention

Risks and Mitigations

| Risk | Mitigation |
|------|------------|
| Tumorigenesis risk (β-catenin) | Use isoform-selective inhibitors |
| Peripheral toxicity | Optimize brain penetration |
| Narrow therapeutic window | Careful dose titration |
| Wnt pathway disruption | Monitor GI effects |

External Links

[PubMed](https://pubmed.ncbi.nlm.nih.gov/)
[KEGG Pathways](https://www.genome.jp/kegg/pathway.html)

References

[Beurel E, Grieco SF, Jope RS, Glycogen synthase kinase-3 (GSK3): regulation, functions, and drug resistance (2015)](https://pubmed.ncbi.nlm.nih.gov/25620652/))

[Llorens-Marítin M, Jury N, Pearn ML, et al, GSK-3β, a pivotal kinase in Alzheimer disease (2014)](https://pubmed.ncbi.nlm.nih.gov/24944265/))

[Hernandez F, Avila J, Tauopathies: cell biology and mechanisms (2023)](https://pubmed.ncbi.nlm.nih.gov/18509338/))

[Palomo V, Pérez DI, Pérez C, et al, Glycogen synthase kinase 3 inhibitors in the pipeline for neurodegenerative diseases (2022)](https://pubmed.ncbi.nlm.nih.gov/34928456/))

📖 View canonical wiki page →

GSK-3 Inhibitor Therapy for Neurodegeneration

Overview

Executive Summary

Mechanism of Action

GSK-3 Biology

Overview

Executive Summary

Mechanism of Action

GSK-3 Biology

Therapeutic Rationale

Inhibitor Classes

Scoring (10-Dimension Rubric)

Clinical Evidence

Completed Trials

Ongoing Trials

Development Pathway

Challenges

Combination Potential

Actionable Next Steps

Lab Experiments

Clinical Protocol Design

Company Partnership Opportunities

Implementation Roadmap

Phase 1: Lead Optimization (Months 1-18)

Phase 2: IND-Enabling Studies (Months 15-30)

Phase 3: Clinical Development (Months 30-60)

Phase 4: Pivotal Trials (Months 60-96)

Key Academic Centers

Industry Partners

Milestones and Go/No-Go Decision Points

Risks and Mitigations

External Links

See Also

References